新西兰婴幼儿和儿童中无细胞百日咳疫苗各剂次接种后的年龄别有效性
该研究采用巢式病例对照设计,利用2006年1月至2013年12月新西兰国家医疗数据,评估6周至7岁儿童接种无细胞百日咳疫苗的剂次特异性有效性。结果显示,婴儿5-11月龄完成三剂后预防住院的有效性为93%(95%CI:87,96),保护持续至4岁生日(VE≥91%);4岁首剂加强后4岁儿童VE为93%(95%CI:90,95),持续至7岁(VE≥91%)。结论支持3剂基础免疫、4岁前不加强的接种方案。
要点
- 5-11月龄婴儿三剂无细胞百日咳疫苗预防住院VE为93%(95%CI:87,96),保护持续至4岁。
- 非住院百日咳VE从5-11月龄的86%降至3岁时的84%,三剂后保护持续。
- 4岁首剂加强后VE为93%(95%CI:90,95),持续至7岁(VE≥91%)。
核心结论
- 基础免疫和首剂加强后均保持高水平保护且VE未见下降,支持3剂基础免疫、4岁前不加强的无细胞疫苗方案。
研究设计与样本
- 巢式病例对照研究,使用2006年1月至2013年12月新西兰全国医疗数据,纳入6周至7岁住院和非住院百日咳儿童,通过国家免疫登记获取接种状态,条件logistic回归计算剂次特异性VE。
主要发现
- 5-11月龄婴儿三剂对比零剂预防住院VE为93%(95%CI:87,96),保护持续至4岁生日(VE≥91%)。
- 非住院百日咳三剂后VE从5-11月龄的86%(95%CI:80,90)至3岁时的84%(95%CI:80,88),保护持续。
- 4岁首剂加强后4岁儿童VE为93%(95%CI:90,95),持续至7岁(VE≥91%)。
关键数值与推荐
- 5-11月龄婴儿三剂对比零剂预防住院VE为93%(95%CI:87,96)。
- 5-11月龄婴儿三剂后非住院VE为86%(95%CI:80,90)。
- 3岁儿童三剂后非住院VE为84%(95%CI:80,88)。
- 4岁儿童首剂加强后VE为93%(95%CI:90,95)。
临床怎么用
- 作者认为研究结果支持3剂无细胞疫苗基础免疫、4岁前不加强的接种方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Though it is believed the switch from whole cell to acellular pertussis vaccine has contributed to the resurgence of pertussis disease, few studies have evaluated vaccine effectiveness (VE) and duration of protection provided by an acellular vaccine schedule including three primary doses but no toddler-age dose. We assessed this schedule in New Zealand (NZ), a setting with historically high rates of pertussis disease, and low but recently improved immunisation coverage. We further evaluated protection following the preschool-age booster dose. METHODS: We performed a nested case-control study using national-level healthcare data. Hospitalised and non-hospitalised pertussis was detected among children 6weeks to 7years of age between January 2006 and December 2013. The NZ National Immunisation Register provided vaccination status for cases and controls. Conditional logistic regression was used to calculate dose-specific VE with duration of immunity examined by stratifying VE into ages aligned with the immunisation schedule. RESULTS: VE against pertussis hospitalisation was 93% (95% confidence interval [CI]: 87, 96) following three doses among infants aged 5-11months who received three compared to zero doses. This protection was sustained through children's fourth birthdays (VE⩾91%). VE against non-hospitalised pertussis was also sustained after three doses, from 86% (95% CI: 80, 90) among 5-11month olds to 84% (95% CI: 80, 88) among 3-year-olds. Following the first booster dose at 4years of age, the protective VE of 93% (95% CI: 90, 95) among 4-year-olds continued through 7years of age (VE⩾91%). CONCLUSIONS: We found a high level of protection with no reduction in VE following both the primary course and the first booster dose. These findings support a 3-dose primary course of acellular vaccine with no booster dose until 4years of age.
引用
- Radke S, Petousis-Harris H, Watson D, et al. Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand. Vaccine. 2016. PMID: 27866766. doi:10.1016/j.vaccine.2016.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。